You are here

Share:

Search Technologies

Showing 1-20 of 62 results found

Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome

Scientists at the National Cancer Institute (NCI) have developed SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a computational precision-oncology framework harnessing genetic interactions to improve treatment options for cancer patients. NCI seeks collaborators or licensees to advance the development of this technology into precision diagnostics.

CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles

Scientists at the National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig), a software-based platform that provides both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. NCI seeks collaborators or licensees to advance the development of CytoSig for research, target discovery, or as a Clinical Decision Support System (CDSS).

A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays

Researchers at the National Cancer Institute (NCI) have developed a monoclonal antibody against ataxia telangiectasia-mutated and Rad3-related (ATR) kinase phosphorylated at threonine 1989. The antibody can be used for pharmacodynamic assays to quantify drug action on the ATR target.

Zirconium-89 PET Imaging Agent for Cancer

This technology is a new generation of rationally designed chelating agents that improve the complexation of Zirconium-89 for PET imaging of cancers.

Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C

NCI Researchers have discovered Interferon-lambda 4 (IFNL4), a protein found through analysis of genomic data. Preliminary studies indicate that this protein may play a role in the clearance of HCV and may be a new target for diagnosing and treating HCV infection. The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) Immunoepidemiology Branch is seeking statements of capability or interest from parties interested in in-licensing or collaborative research to further co-develop a gene-based diagnostic for Hepatitis C virus (HepC, HCV).

A Gene-Based Prognostic for Hepatocellular Carcinoma Patient Response to Adjuvant Transcatheter Arterial Chemoembolization

The gold standard of care for hepatocellular carcinoma patients with intermediate- to locally advanced tumors is transcatheter arterial chemoembolization (TACE), a procedure whereby the tumor is targeted both with local chemotherapy and restriction of local blood supply. NCI scientists have identified a 14-gene signature predictive of response to TACE, and NCI seeks licensees or co-development partners to develop the technology toward commercialization.

Non-invasive diagnostic and prognostic assay for early stage lung cancer

NCI scientists developed a method that uses urine samples to detect early-stage cancers and that could supplement low-dose computed tomography (LD-CT) for early-stage cancer detection, and significantly decrease expensive false negative/false positive results. The NCI seeks co-developers or licensees to commercialize this technology.

Prognostic Biomarkers for Patients with Early Stage Lung Cancer

Investigators at the National Cancer Institute discovered a set of biomarkers that can identify patients with early stage lung cancer who are at a high risk of relapse. These prognostic methods can guide physicians to select appropriate treatment and follow-up while sparing other patients of unnecessary treatment and negative side-effects of chemotherapy. The NCI seeks parties to license or co-develop the invention.

High-throughput Assay to Identify New Cancer Drugs

The National Cancer Institute seeks parties interested in collaborative research to evaluate or commercialize a diagnostic tool that can identify new drugs that increase chromosome instability.

Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics

Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.

Clinical Outcome Predictors for Mantle Cell Lymphoma

The invention is a novel methodology for predicting a mantle cell lymphoma (MCL) cancer patient’s survival prognosis. This information is important in helping determine the best course of treatment for the patient.

Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic

This technology consists of highly specific rabbit monoclonal antibodies reactive with phosphorylated tyrosine located at amino acid 1235 in the human MET sequence. Binding to this pYl235 residue is independent of the phosphorylation of other tyrosines in the vicinity (1230 and 1234), does not cross-react with these nearby phosphotyrosine residues, and does not occur when Y1235 is unphosphorylated. Researchers at the NCI seek licensing and/or co-development research collaborations  to commercialize and develop a companion diagnostic for selective MET inhibitors.

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.

Quantitative In Vivo Methods for Measuring Brain Networks

Researchers at the NICHD seek licensing and/or co-development research collaborations for a Magnetic Resonance Imaging (MRI) method to quantitatively measure in vivo the estimated conduction time of nerve impulses in the brain.

3D Image Rendering Software for Biological Tissues

The Frederick National Laboratory for Cancer Research seeks parties interested in collaborative research to co-develop software for the automatic 3-D visualization of biological image volumes.

Pages